



MARCUS VETTER
Switzerland

Personal statement

My motivation to join the ESGO Council arises from a longstanding commitment to advancing excellence and innovation in gynaecological and breast cancer oncology through multidisciplinary collaboration, research, and education.

As Head of the Oncology and Hematology Center at Kantonsspital Baselland, Switzerland, and President of the SAKK Breast Cancer Group, I bring more than two decades of clinical and academic experience that align closely with ESGO's mission to improve the quality of care for women with cancer across Europe. Throughout my career, I have led numerous clinical and translational research projects focused on improving therapeutic strategies in breast and gynaecological cancers.

My leadership within SAKK has involved developing pragmatic, patient-centered clinical trials and fostering collaboration between academia and industry to ensure access to innovative therapies. Our projects have addressed key issues such as treatment optimization, supportive care, and inclusion of underrepresented populations—principles that mirror ESGO's emphasis on equitable, evidence-based oncology.

In parallel, my translational research—conducted in collaboration with the University Hospital Basel and ETH Zurich—has produced high-impact publications in *Nature*, *Cell*, and *Breast Cancer Research*, exploring mechanisms of metastasis and circulating tumor cells. This experience strengthens my ability to contribute to ESGO's goal of bridging basic science with clinical practice to improve patient outcomes.

As Switzerland's national representative for the International Society of Geriatric Oncology (SIOG), I have also championed the integration of geriatric assessment and individualized care for older cancer patients. This perspective on inclusivity and patient diversity would contribute to ESGO's efforts to address the needs of all women, regardless of age or background. I am driven by a passion for mentorship, education, and cross-border collaboration.

Serving on the ESGO Council would allow me to apply my leadership, scientific, and organizational skills to strengthen European cooperation, foster young investigators, and ensure that ESGO remains a global benchmark in women's cancer care and research.

Curriculum Vitae

Personal Information

Name: PD Dr. Marcus Vetter

Date of Birth: 28 January 1975

Nationality: German

Position: Chief Physician, KSBL – Center for Oncology and Hematology

Contact: marcus.vetter@ksbl.ch | +41 61 400 2715

Education and Qualifications

2013 – FMH Medical Oncology, Basel

2012 – FMH General Internal Medicine, Basel

2009 – MD, Marburg University, Germany (summa cum laude)

2018 – Habilitation, Medical Oncology, University of Basel

Professional Experience

2021–present: Chief Physician, KSBL Center for Oncology and Hematology

2018–2021: Senior Consultant, University Hospital Basel, Oncology

2012–2018: Attending Physician, University Hospital Basel, Oncology

2011: Clinical Research Fellow, Royal Marsden Hospital, London

Leadership and Memberships

- Board Member, Swiss Geriatric Oncology Group (SAKK)
- National Representative, International Society for Geriatric Oncology (SIOG) since 2022
- Board Member, SIOG since 2024
- President, Breast Cancer Working Group of SAKK since 2023

Research Focus

Breast cancer, gynecological tumors, geriatric oncology, and translational research.

Key projects: Circulating Tumor Cells in breast cancer (NCT03928210), Swiss Ovar Registry (SAKK), and VOICE Recognition in older cancer patients (NCT05783401).

Teaching Activities

Lecturer for students of Human and Dental Medicine at the University of Basel.

- 2018–present: AP Teaching, Oncology Skills Lab, University of Basel
- 2018–present: Lectures on Multimodal Therapy of Ovarian Cancer
- 2019–2024: Tutorials on Clinical and Scientific Reasoning
- 2021–2024: Seminars on Geriatric Oncology and Translational Research
- Supervising Master's theses and MD dissertations in Oncology and Geriatrics

Research Grants and Third-Party Funding

2025–2026: CARE-INSIGHTS project (KLS) – CHF 128,000

2024: SAKK/AbbVie Digital Innovation Award – CHF 30,000

2023: Gilead SAKK Award in Geriatric Oncology – CHF 40,000

2020: Krebsliga Schweiz – Personalized treatment for ER-positive metastatic breast cancer – CHF 354,000

2020: Krebsliga beider Basel – Effects of synthetic glucocorticoid administration in breast cancer patients – CHF 30,000

2019: Krebsliga beider Basel – Effect of Digoxin on CTC clusters in breast cancer – CHF 51,000

2023–2026: Swiss Ovar Registry (GSK Pharma) – CHF 750,000

Selected Invited Talks (since 2021)

- 2024: Swiss-ECHO Hot Topic: Breast Cancer ADC Revolution
- 2023: BBC Basel – TNBC is a curable disease step by step
- 2023: SASRO Congress Bern – Geriatric Oncology
- 2023: Healthbook – Post-ASCO Highlights
- 2022: Pfizer Ad Board – Meet the Experts
- 2021: Weiterbildung KSBL – Geriatric Oncology

Publikationsliste (seit Habilitation) PD Dr. med .Marcus Vetter

OCRID: 0009-0004-1003-1078

Originalarbeiten in Peer Reviewed-Journals als Erst- oder Letztautor
(Allfällige aus Forschungsaufenthalten hervorgegangene Originalarbeiten kennzeichnen*)

Nr.	Autoren / Titel / Zeitschrift / Band / Seitenzahlen / Jahr	IF ¹
1	Javier-González M, Boulahssass R, Lago LD, González-Senac NM, Nair S, Vetter M. Survey on current clinical practice in geriatric oncology: the individual experience in five European Cancer Centers. Eur Geriatr Med. 2024 Oct 23. doi: 10.1007/s41999-024-01041-7. Epub ahead of print. PMID: 39441518.	3.5
2	Petit-Berli M, Knufinke M, Voegeli M, Sonderegger M, Seifert B, Chiru ED, Haeuptle P, Van't Walderveen L, Rosenberg R, Burri E, Subotic S, Schwab FD, Dougoud-Chauvin V, Unger H, Mertz K, Tahan L, Vetter M. Precision Oncology in Older Cancer Patients: A Single-Center Experience. Int J Mol Sci. 2024 Oct 21;25(20):11322. doi: 10.3390/ijms252011322. PMID: 39457104; PMCID: PMC11508622.	4.9
3	Chiru ED, Oseledchik A, Schoetzau A, Kurzeder C, Mosimann R, Vetter M, Grašič Kuhar C. Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx. Diagnostics (Basel). 2023 Dec 31;14(1):97. doi: 10.3390/diagnostics14010097. PMID: 38201405; PMCID: PMC10795714. Equally contributed	3.0
4	Wallrabenstein T, Oseledchik A, Daetwyler E, Rochlitz C, Vetter M. Upfront Taxane Could Be Superior to Pegylated Liposomal Doxorubicin (PLD): A Retrospective Real-World Analysis of Treatment Sequence Taxane-PLD versus PLD-Taxane in Patients with Metastatic Breast Cancer. Cancers (Basel). 2023 Oct 12;15(20):4953. doi: 10.3390/cancers15204953. PMID: 37894320; PMCID: PMC10605604.	4.5
5	Chiru ED, Grasic Kuhar C, Oseledchik A, Schötzau A, Gonzalez MJ, Kurzeder C, Vetter M. Clinical application of the 21-gene oncotype recurrence score in an older cohort: A single center experience. Transl Oncol. 2023 Oct;36:101724. doi: 10.1016/j.tranon.2023.101724. Epub 2023 Jul 20. PMID: 37480708; PMCID: PMC10375846.	4.5
6	Dettwiler D, Chiru ED, Daetwyler E, Dougoud-Chauvin V, Gross MW, Kurzeder C, Zippelius A, Schötzau A, Vetter M. Clinical and pathological factors and outcome of central nervous system metastasis in breast cancer. Front Oncol. 2023 Sep 19;13:1247402. doi: 10.3389/fonc.2023.1247402. PMID: 37795444; PMCID: PMC10546422.	3.5
7	Heidinger M, Simonnet E, Koh LM, Frey Tirri B, Vetter M. Therapeutic approaches in patients with bone metastasis due to endometrial carcinoma - A systematic review. J Bone Oncol. 2023 May 15;41:100485. doi: 10.1016/j.jbo.2023.100485. PMID: 37250286; PMCID: PMC10213377.	3.1
8	Biskup E, Sartorius CM, Müller A, Leo C, Nussbaum CU, Georgescu Margarint EL, Koychev D, Schreiber A, Taverna C, Thorn D, Vetter M. Pertuzumab as second- or later-line therapy for human epidermal growth factor receptor 2-positive metastatic breast cancer: A clinical experience. Mol Clin Oncol. 2023 May 18;19(1):52. doi: 10.3892/mco.2023.2648. PMID: 37303973; PMCID: PMC10251341.	1.4
9	Grasic Kuhar C, Gortnar Cepeda T, Kurzeder C, Vetter M. Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population. Radiol Oncol. 2023 Jun 21;57(2):211-219. doi: 10.2478/raon-2023-0019. PMID: 37341200; PMCID: PMC10286894.	2.1
10	Wallrabenstein T, Daetwyler E, Oseledchik A, Rochlitz C, Vetter M. Pegylated liposomal doxorubicin (PLD) in daily practice-A single center experience of treatment with PLD in patients with comorbidities and older patients with metastatic breast cancer. Cancer Med. 2023 Jun;12(12):13388-13396. doi: 10.1002/cam4.6041. Epub 2023 May 6. PMID: 37148541; PMCID: PMC10315717.	2.9
11	Vetter M, Stadlmann S, Bischof E, Georgescu Margarint EL, Schötzau A, Singer G, Heinzelmann-Schwarz V, Montavon C. Hormone Receptor Expression in Primary and Recurrent High-Grade Serous Ovarian Cancer and Its Implications in Early Maintenance	4.9

	Treatment. Int J Mol Sci. 2022 Nov 17;23(22):14242. doi: 10.3390/ijms232214242. PMID: 36430718; PMCID: PMC9692716.	
12	Bischof E, Schwab FD, Georgescu Margarint EL, Montavon C, Zünti I, Schollbach A, Schötzau A, Hirschmann A, Landin J, Meier C, Christian K, Vetter M. Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience. Bone Rep. 2021 Dec 11;16:101160. doi: 10.1016/j.bonr.2021.101160. PMID: 34977282; PMCID: PMC8685978.	2.1
13	Vetter M, Rothgiesser KM, Li Q, Hawle H, Schönfeld W, Ribi K, Riniker S, von Moos R, Trojan A, Kralidis E, Fehr M, Müller A, Thürlimann B; Swiss Group for Clinical Cancer Research (SAKK). SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients. Endocr Oncol. 2022 Feb 10;2(1):9-18. doi: 10.1530/EO-21-0009. PMID: 37435469; PMCID: PMC10259314.	1.2
14	Vetter M, Landin J, Szczerba BM, Castro-Giner F, Gkountela S, Donato C, Krol I, Scherrer R, Balmelli C, Malinowska A, Zippelius A, Kurzeder C, Heinzelmänn-Schwarz V, Weber WP, Rochlitz C, Aceto N. Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancer. Breast Cancer Res. 2018 Nov 20;20(1):141. doi: 10.1186/s13058-018-1067-y. PMID: 30458879; PMCID: PMC6247738.	6.1

¹Impact Faktoren

²Fachspezifisches Ranking

Originalarbeiten in Peer Reviewed-Journals als Mitautor

Nr.	Autoren / Titel / Zeitschrift / Band / Seitenzahlen / Jahr	IF1
1	Creutzberg CL, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park JY, Lorusso D, Mileschkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebiski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W Jr, Miller A, Concin N, Powell MA, Stuart G, Bookman MA; participants of the 2023 Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical Research. Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup. Lancet Oncol. 2024 Sep;25(9):e420-e431. doi: 10.1016/S1470-2045(24)00192-X. PMID: 39214113. (Im Paper als Pannelist erwähnt)	41.6
2	Cathomas M, Taha A, Kunst N, Burri E, Vetter M, Galli R, Rosenberg R, Heigl A. Adherence to enhanced recovery after surgery (ERAS) in older adults following colorectal resection. J Geriatr Oncol. 2024 Sep 12;15(8):102062. doi: 10.1016/j.jgo.2024.102062. Epub ahead of print. PMID: 39270426.	3.0
3	Immer A, Stark SG, Jacob F, Bonilla X, Thomas T, Kahles A, Goetze S, Milani ES, Wollscheid B; Tumor Profiler Consortium; Rätsch G, Lehmann KV. Probabilistic pathway-based multimodal factor analysis. Bioinformatics. 2024 Jun 28;40(Suppl 1):i189-i198. doi: 10.1093/bioinformatics/btae216. PMID: 38940152; PMCID: PMC11256960. (Tumorprofilerconsortium M. Vetter)	4.4
4	Grašič Kuhar C, Geiger J, Schwab FD, Heinzelmänn-Schwartz V, Vetter M, Weber WP, Kurzeder C. Prognostic Importance of Axillary Lymph Node Response to Neoadjuvant Systemic Therapy on Axillary Surgery in Breast Cancer-A Single Center Experience. Cancers (Basel). 2024 Mar 27;16(7):1306. doi: 10.3390/cancers16071306. PMID: 38610984; PMCID: PMC11010874.	4.5
5	Zwimpfer TA, Bilir E, Gasimli K, Cokan A, Bizzarri N, Razumova Z, Kacperczyk-Bartnik J, Nikolova T, Pletnev A, Kahramanoglu I, Shushkevich A, Strojna A, Theofanakis C, Cicakova T, Vetter M, Montavon C, Morgan G, Heinzelmänn-Schwarz V. Management of Patients with Hypersensitivity to Platinum Salts and Taxane in Gynecological Cancers: A Cross-Sectional Study by the European Network of Young Gynaecologic Oncologists (ENYGO). Cancers (Basel). 2024 Mar 14;16(6):1155. doi: 10.3390/cancers16061155. PMID: 38539490; PMCID: PMC10969349.	4.5
6	Mizutani T, Cheung KL, Hakobyan Y, Lane H, Decoster L, Karnakis T, Puts M, Calderon O, Jørgensen TL, Boulahssass R, Wedding U, Karampeazis A, Chan WWL, Banerjee J, Falci	3.0

	C, van Leeuwen BL, Fonseca V, Gironés Sarrió R, Vetter M, Dougoud V, Naeim A, Ashman J, Musolino N, Kanavaras R. Leave no one behind: A global survey of the current state of geriatric oncology practice by SIOG national representatives. <i>J Geriatr Oncol</i> . 2024 Mar;15(2):101709. doi: 10.1016/j.jgo.2024.101709. Epub 2024 Feb 3. PMID: 38310661.	
7	Zwimpfer TA, Scherer K, Schötzau A, Heinzelmann-Schwarz V, Hartmann K, Vetter M, Montavon C. Desensitization in patients with hypersensitivity to platinum and taxane in gynecological cancers. <i>Cancer Med</i> . 2024 Jan;13(1):e6840. doi: 10.1002/cam4.6840. Epub 2023 Dec 22. PMID: 38140783; PMCID: PMC10807606.	2.9
8	Hamelin B, Obradović MMS, Sethi A, Kloc M, Müntz S, Beisel C, Eschbach K, Kohler H, Soysal S, Vetter M, Weber WP, Stadler MB, Bentires-Alj M. Single-cell Analysis Reveals Inter- and Intratumour Heterogeneity in Metastatic Breast Cancer. <i>J Mammary Gland Biol Neoplasia</i> . 2023 Dec 8;28(1):26. doi: 10.1007/s10911-023-09551-z. PMID: 38066300; PMCID: PMC10709262.	3.0
9	Dondi A, Lischetti U, Jacob F, Singer F, Borgsmüller N, Coelho R; Tumor Profiler Consortium; Heinzelmann-Schwarz V, Beisel C, Beerenwinkel N. Detection of isoforms and genomic alterations by high-throughput full-length single-cell RNA sequencing in ovarian cancer. <i>Nat Commun</i> . 2023 Nov 27;14(1):7780. doi: 10.1038/s41467-023-43387-9. PMID: 38012143; PMCID: PMC10682465. (Tumorprofilerconsortium M. Vetter)	14.7
10	Allemann-Su YY, Vetter M, Koechlin H, Conley Y, Paul SM, Cooper BA, Kober KM, Levine JD, Miaskowski C, Katapodi MC. Distinct Cognitive Function Profiles Are Associated With a Higher Presurgery Symptom Burden in Patients With Breast Cancer. <i>Cancer Nurs</i> . 2023 Jul-Aug 01;46(4):E208-E217. doi: 10.1097/NCC.0000000000001114. Epub 2022 Apr 12. PMID: 35439196; PMCID: PMC11186600.	2.4
11	Prummer M, Bertolini A, Bosshard L, Barkmann F, Yates J, Boeva V; Tumor Profiler Consortium; Stekhoven D, Singer F. scROSH: robust supervised hierarchical identification of single cells. <i>NAR Genom Bioinform</i> . 2023 Jun 16;5(2):lqad058. doi: 10.1093/nargab/lqad058. PMID: 37332656; PMCID: PMC10273189. (Tumorprofilerconsortium M. Vetter)	4.0
12	Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjak S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O; International Breast Cancer Study Group; POSITIVE Trial Collaborators. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer. <i>N Engl J Med</i> . 2023 May 4;388(18):1645-1656. doi: 10.1056/NEJMoa2212856. PMID: 37133584; PMCID: PMC10358451. (Investigator M. Vetter)	96.3
13	Restivo G, Tastanova A, Balázs Z, Panebianco F, Diepenbruck M, Ercan C, Preca BT, Hafner J, Weber WP, Kurzeder C, Vetter M, Soysal SM, Beisel C, Bentires-Alj M, Piscuoglio S, Krauthammer M, Levesque MP. Live slow-frozen human tumor tissues viable for 2D, 3D, ex vivo cultures and single-cell RNAseq. <i>Commun Biol</i> . 2022 Oct 28;5(1):1144. doi: 10.1038/s42003-022-04025-0. PMID: 36307545; PMCID: PMC9616892.	5.2
14	Allemann-Su YY, Vetter M, Koechlin H, Paul SM, Cooper BA, Oppegaard K, Melisko M, Levine JD, Conley Y, Miaskowski C, Katapodi MC. Pre-Surgery Demographic, Clinical, and Symptom Characteristics Associated with Different Self-Reported Cognitive Processes in Patients with Breast Cancer. <i>Cancers (Basel)</i> . 2022 Jul 5;14(13):3281. doi: 10.3390/cancers14133281. PMID: 35805053; PMCID: PMC9265628.	4.5
15	Eichhoff OM, Stoffel CI, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng PF, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan VS, Wenzina J, Aloia A, Saltari A, Dzung A; TuPro Consortium; Krauthammer M, Schreiber SL, Hornemann T, Distel M, Snijder B, Dummer R, Levesque MP. ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma. <i>Cancer Res</i> . 2023 Apr 4;83(7):1128-1146. doi: 10.1158/0008-5472.CAN-22-1826. PMID: 36946761.	12.5
16	Diamantopoulou Z, Castro-Giner F, Schwab FD, Foerster C, Saini M, Budinjas S, Strittmatter K, Krol I, Seifert B, Heinzelmann-Schwarz V, Kurzeder C, Rochlitz C, Vetter M, Weber WP, Aceto N. The metastatic spread of breast cancer accelerates during sleep. <i>Nature</i> . 2022 Jul;607(7917):156-162. doi: 10.1038/s41586-022-04875-y. Epub 2022 Jun 22. PMID: 35732738.	50.5
17	Scheidmann MC, Castro-Giner F, Strittmatter K, Krol I, Paasinen-Sohns A, Scherrer R, Donato C, Gkoutela S, Szczerba BM, Diamantopoulou Z, Muenst S, Vlainic T, Kunz L,	12.5

-
-
- Vetter M, Rochlitz C, Taylor V, Giachino C, Schroeder T, Platt RJ, Aceto N. An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression. *Cancer Res.* 2022 Feb 15;82(4):681-694. doi: 10.1158/0008-5472.CAN-21-3908. PMID: 34916221; PMCID: PMC7612409.
-
- 18 Correia AL, Guimaraes JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, Bruno S, Schmidt A, Mertz K, Volkmann K, Terracciano L, Zippelius A, Vetter M, Kurzeder C, Weber WP, Bentires-Alj M. Author Correction: Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. *Nature.* 2021 Dec;600(7887):E7. doi: 10.1038/s41586-021-04104-y. Erratum for: *Nature.* 2021 Jun;594(7864):566-571. doi: 10.1038/s41586-021-03614-z. PMID: 34764479. 50.5
-
- 19 Sobottka B, Nowak M, Frei AL, Haberecker M, Merki S; Tumor Profiler consortium; Levesque MP, Dummer R, Moch H, Koelzer VH. Establishing standardized immune phenotyping of metastatic melanoma by digital pathology. *Lab Invest.* 2021 Dec;101(12):1561-1570. doi: 10.1038/s41374-021-00653-y. Epub 2021 Aug 26. Erratum in: *Lab Invest.* 2021 Dec;101(12):1637. doi: 10.1038/s41374-021-00676-5. PMID: 34446805; PMCID: PMC8590976. 5.1
-
- 20 Correia AL, Guimaraes JC, Auf der Maur P, De Silva D, Trefny MP, Okamoto R, Bruno S, Schmidt A, Mertz K, Volkmann K, Terracciano L, Zippelius A, Vetter M, Kurzeder C, Weber WP, Bentires-Alj M. Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy. *Nature.* 2021 Jun;594(7864):566-571. doi: 10.1038/s41586-021-03614-z. Epub 2021 Jun 2. Erratum in: *Nature.* 2021 Dec;600(7887):E7. doi: 10.1038/s41586-021-04104-y. PMID: 34079127. 50.5
-
- 21 Irmisch A, Bonilla X, Chevrier S, Lehmann KV, Singer F, Toussaint NC, Esposito C, Mena J, Milani ES, Casanova R, Stekhoven DJ, Wegmann R, Jacob F, Sobottka B, Goetze S, Kuipers J, Sarabia Del Castillo J, Prummer M, Tuncel MA, Menzel U, Jacobs A, Engler S, Sivapatham S, Frei AL, Gut G, Ficek J, Miglino N; Tumor Profiler Consortium; Aebbersold R, Bacac M, Beerenwinkel N, Beisel C, Bodenmiller B, Dummer R, Heinzelmann-Schwarz V, Koelzer VH, Manz MG, Moch H, Pelkmans L, Snijder B, Theodorides APA, Tolnay M, Wicki A, Wollscheid B, Ratsch G, Levesque MP. The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support. *Cancer Cell.* 2021 Mar 8;39(3):288-293. doi: 10.1016/j.ccell.2021.01.004. Epub 2021 Jan 21. PMID: 33482122. Tumorprofiler M. Vetter 48.8
-
- 22 Mayer EL, Dueck AC, Martin M, Rubovszky G, Burstein HJ, Bellet-Ezquerria M, Miller KD, Zdenkowski N, Winer EP, Pfeiler G, Goetz M, Ruiz-Borrego M, Anderson D, Nowecki Z, Loibl S, Moulder S, Ring A, Fitzal F, Traina T, Chan A, Rugo HS, Lemieux J, Henao F, Lyss A, Antolin Novoa S, Wolff AC, Vetter M, Egle D, Morris PG, Mamounas EP, Gil-Gil MJ, Prat A, Fohler H, Metzger Filho O, Schwarz M, DuFrane C, Fumagalli D, Theall KP, Lu DR, Bartlett CH, Koehler M, Fesl C, DeMichele A, Gnant M. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol.* 2021 Feb;22(2):212-222. doi: 10.1016/S1470-2045(20)30642-2. Epub 2021 Jan 15. PMID: 33460574. 41.6
-
- 23 Stark SG, Ficek J, Locatello F, Bonilla X, Chevrier S, Singer F; Tumor Profiler Consortium; Ratsch G, Lehmann KV. SCIM: universal single-cell matching with unpaired feature sets. *Bioinformatics.* 2020 Dec 30;36(Suppl_2):i919-i927. doi: 10.1093/bioinformatics/btaa843. PMID: 33381818; PMCID: PMC7773480. 4.4
-
- 24 Donato C, Kunz L, Castro-Giner F, Paasinen-Sohns A, Strittmatter K, Szczerba BM, Scherrer R, Di Maggio N, Heusermann W, Biehlmaier O, Beisel C, Vetter M, Rochlitz C, Weber WP, Banfi A, Schroeder T, Aceto N. Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells. *Cell Rep.* 2020 Sep 8;32(10):108105. doi: 10.1016/j.celrep.2020.108105. PMID: 32905777; PMCID: PMC7487783. 7.5
-
- 25 Kohler C, Chang M, Allemann-Su YY, Vetter M, Jung M, Jung M, Conley Y, Paul S, Kober KM, Cooper BA, Smoot B, Levine JD, Miaskowski C, Katapodi MC. Changes in Attentional Function in Patients From Before Through 12 Months After Breast Cancer Surgery. *J Pain Symptom Manage.* 2020 Jun;59(6):1172-1185. doi: 10.1016/j.jpainsymman.2020.01.001. Epub 2020 Jan 15. PMID: 31953207; PMCID: PMC7239765. 3.2
-
- 26 Heinzelmann-Schwarz V, Kind AB, Vetter M, Russell K, Omar S, Schoetza A, Hoeck K, Fink D, Friedlander ML, Hacker NF. Should MGMT still be treated with adjuvant taxane-based combination chemotherapy? *J Cancer Res Clin Oncol.* 2020 Mar;146(3):695-704. doi: 10.1007/s00432-019-03091-y. Epub 2020 Jan 28. PMID: 31993743; PMCID: PMC7039840. 2.7

-
- 27 Gkountela S, Castro-Giner F, Szczerba BM, Vetter M, Landin J, Scherrer R, Krol I, Scheidmann MC, Beisel C, Stirnimann CU, Kurzeder C, Heinzelmann-Schwarz V, Rochlitz C, Weber WP, Aceto N. Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding. *Cell*. 2019 Jan 10;176(1-2):98-112.e14. doi: 10.1016/j.cell.2018.11.046. PMID: 30633912; PMCID: PMC6363966. 45.6
-
- 28 Szczerba BM, Castro-Giner F, Vetter M, Krol I, Gkountela S, Landin J, Scheidmann MC, Donato C, Scherrer R, Singer J, Beisel C, Kurzeder C, Heinzelmann-Schwarz V, Rochlitz C, Weber WP, Beerenwinkel N, Aceto N. Neutrophils escort circulating tumour cells to enable cell cycle progression. *Nature*. 2019 Feb;566(7745):553-557. doi: 10.1038/s41586-019-0915-y. Epub 2019 Feb 6. PMID: 30728496. 50.5